DURATOCIN DIN 02496526
Health Canada record
| Active ingredient(s) | CARBETOCIN 100 MCG |
|---|---|
| Dosage form | Solution |
| Route | Intravenous; Intramuscular |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | H01BB03 CARBETOCIN |
| Original market date | 05-Aug-2020 |
| Current status date | 05-Aug-2020 |
| Source | Health Canada DPD |
Establishment licence of the holder
Ferring Inc. — licence 100274, currently licensed, last inspection rating C (2026-05-19).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing CARBETOCIN
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02489244 | CARBETOCIN INJECTION | JUNO PHARMA CANADA INC. | Solution | CARBETOCIN 100 MCG | Marketed |
| 02231593 | DURATOCIN | FERRING INC | Solution | CARBETOCIN 100 MCG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 23249 | 2020-02-24 | Supplement to a New Drug Submission (SNDS) | EXPAND THE INDICATION AND ADD A NEW ROUTE OF ADMINISTRATION |
International API supply for CARBETOCIN
1 active FDA Drug Master Files.
Request a quote for DURATOCIN